Therapeutic | Efalizumab |
Target | ITGAL |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK |
100% seqID Fv Structure | 3eo9 [Fvs: HL], 3eoa [Fvs: BA, HL], 3eob [Fvs: BA, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3eo9 [Fvs: HL] |
100% seqID Structure | 3eoa [Fvs: BA, HL] |
100% seqID Structure | 3eob [Fvs: BA, HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2001 |
INN Year Recommended | 2002 |
Companies Involved | Genentech, Merck Serono, XOMA |
Conditions Approved | Psoriasis |
Conditions Active | na |
Conditions Discontinued | Psoriatic arthritis, Type 1 diabetes mellitus |
Notes |